Overview

Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

Status:
Active, not recruiting

Trial end date:
2022-08-01

Target enrollment:
0

Participant gender:
All

Summary

Porphyria cutanea tarda (PCT) is an iron-related disorder that responds to treatment by phlebotomy or low-dose hydroxychloroquine, but comparative data on these treatments are limited. The hypothesis is that hydroxychloroquine is noninferior to phlebotomy in terms of time to remission. Patients with well documented PCT are assigned to treatment by randomization if specific criteria are met. All patients are followed until remission - defined as achieving a normal plasma porphyrin concentration.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

The University of Texas Medical Branch, Galveston

Treatments:

Hydroxychloroquine

Criteria

Inclusion Criteria:

- Documented porphyria cutanea tarda (PCT)

- Willing to give informed consent

- Age 18 or greater

Exclusion Criteria:

- Blistering skin lesions due to another condition